This story is from December 07, 2021
FIND and CSIR-IGIB partner to strengthen genomic surveillance of Coronavirus
MUMBAI:
Point-of-care genome sequencing has gained more relevance with the emergence of Omicron, designated a VOC by the World Health Organization (WHO) on November 26, with the need for enhanced sequencing capacity becoming pivotal in tracking new variants and informing accurate tests and appropriate treatment. Point-of-care genome sequencing is designed to combine scale, speed and sensitivity, and is expected to become a gold standard for vigilance, analysis and control of pathogen spread.
The partnership will serve to optimize and scale the capacity needed to identify SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI). It will also serve to identify genomic hotspots, and mutations associated with disease severity that are critical for surveillance and public health action.
Dr
Dr Rajesh Pandey principal scientist, CSIR-IGIB said: “MicroLabs based genome sequencing of pathogens would take labs to the people, allowing for rapid variant detection and prioritising sequencing of clinically relevant samples. This would advance a ‘hub-and-spoke’ model of genomic surveillance, comprising both --MegaLabs (high-throughput sequencing) and MicroLabs (high-priority sequencing). This is especially important as we make progress towards monitoring the ports of entry for possibly tracking of Omicron entry to India. In addition to VOC, understanding the genomic mutations underlying vaccination breakthrough is also equally important and merits tracking through network of MicroLabs.”
Prof Anurag Agrawal director CSIR-IGIB said: “Such efforts are important towards making India better prepared for genomic surveillance of pathogens, with trained genomics manpower, data management and data sharing.”
As a co-lead of the
Stay informed with the latest business news, updates on bank holidays and public holidays.
Boost your business with AI. Join this course by GrowFast and unlock the power of artificial intelligence. Sign up now!
FIND
, a global alliance for diagnostics, is partnering with CSIR-IGIB (Institute of Genomics and Integrated Biology
) to strengthen genomic surveillance of SARS-CoV-2 in the country. The partnership aims to decentralize genomic surveillance of SARS-CoV-2, down to the district level by setting up `microlabs’ that enable sequencing, analysis and interpretation of sequencing data with minimal turnaround time and infrastructure limited settings, says a statement.The partnership will serve to optimize and scale the capacity needed to identify SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI). It will also serve to identify genomic hotspots, and mutations associated with disease severity that are critical for surveillance and public health action.
Dr
Sanjay Sarin
, VP, Access at FIND said: “Omicron has shown us just how vital genomic sequencing is – for monitoring the evolution of the SARS-CoV-2 virus and identifying emerging mutations rapidly to inform public health action locally and globally. Building on our track record of strengthening diagnostic capacity in India as well as our established sequencing programme at FIND, this partnership with CSIR-IGIB will bring sequencing capabilities closer to patients, which means faster response times that can help keep everyone safe.”Dr Rajesh Pandey principal scientist, CSIR-IGIB said: “MicroLabs based genome sequencing of pathogens would take labs to the people, allowing for rapid variant detection and prioritising sequencing of clinically relevant samples. This would advance a ‘hub-and-spoke’ model of genomic surveillance, comprising both --MegaLabs (high-throughput sequencing) and MicroLabs (high-priority sequencing). This is especially important as we make progress towards monitoring the ports of entry for possibly tracking of Omicron entry to India. In addition to VOC, understanding the genomic mutations underlying vaccination breakthrough is also equally important and merits tracking through network of MicroLabs.”
As a co-lead of the
Diagnostics Pillar
of the access to Covid-19 Tools (ACT) Accelerator, FIND is supporting India’s efforts towards establishment of a robust genomic surveillance system. With the second wave of Covid-19 highlighting the importance of focusing on hard-to-reach and rural populations, point-of-care genome sequencing is essential to track the evolution of the virus, it added.Stay informed with the latest business news, updates on bank holidays and public holidays.
Boost your business with AI. Join this course by GrowFast and unlock the power of artificial intelligence. Sign up now!
Popular from Business
- Trump’s tariff gambit: How it’s reshaping India, China, and the global economy
- Savings moving to market-linked financial products expose households to significant risks, warns Finance Ministry
- Soon you may get to pay lower toll charges on national highways - details here
- IT industry faces sluggish growth: Analysts
- Stock market today: BSE Sensex ends almost 900 points up; Nifty50 above 23,150 - top reasons for D-Street rally
end of article
Trending Stories
- March 2025 bank holidays: Are banks closed on Saturday, March 22, 2025?
- Tata Group companies quietly partner with Elon Musk-led Tesla; become global supplier to EV maker
- Stock market today: BSE Sensex opens over 100 points down; Nifty50 near 23,150
- Top stocks to buy today: Stock recommendations for March 21, 2025
- Soon you may get to pay lower toll charges on national highways - details here
- Stock market today: BSE Sensex opens over 400 points up; Nifty50 crosses 23,000
- Top stocks to buy today: Stock recommendations for March 20, 2025
Visual Stories
- 8 tricks to recall anything in seconds during exams
- 8 Ruskin Bond stories that enlighten students about nature and life
- 8 most powerful ways to memorise anything in minutes for exams
- 8 Chanakya Sutras to lead students to success through intelligent effort
- 8 reasons why studying too hard is ruining your test scores
TOP TRENDS
UP NEXT
Start a Conversation
Post comment